Qijun Li Yong Dong Yubin Pan Honglin Tang Da Li
10.3389/fimmu.2021.634559
Front Immunol
2021 Mar 31;12:634559.
b-cell indolent lymphoma case report double primary tumors hepatocellular carcinoma immune checkpoint inhibitors misdiagnosis tislelizumab
CC BY
https://pubmed.ncbi.nlm.nih.gov/33868256/
Antibodies, Monoclonal, Humanized / therapeutic use Carcinoma, Hepatocellular / drug therapy Immune Checkpoint Inhibitors / therapeutic use Liver Neoplasms / drug therapy Lymphoma, B-Cell / drug therapy Neoplasms, Multiple Primary / drug therapy
Antibodies, Monoclonal, Humanized / therapeutic use Carcinoma, Hepatocellular / drug therapy Immune Checkpoint Inhibitors / therapeutic use Liver Neoplasms / drug therapy Lymphoma, B-Cell / drug therapy Neoplasms, Multiple Primary / drug therapy Case Reports Research Support, Non-U.S. Gov't Review Carcinoma, Hepatocellular / diagnostic imaging Carcinoma, Hepatocellular / immunology Carcinoma, Hepatocellular / metabolism Humans Liver Neoplasms / diagnostic imaging Liver Neoplasms / immunology Liver Neoplasms / metabolism Lymphoma, B-Cell / diagnostic imaging Lymphoma, B-Cell / immunology Lymphoma, B-Cell / metabolism Male Middle Aged Neoplasms, Multiple Primary / diagnostic imaging Neoplasms, Multiple Primary / immunology Neoplasms, Multiple Primary / pathology Treatment Outcome Antibodies, Monoclonal, Humanized Immune Checkpoint Inhibitors tislelizumab
PMC8044442
33868256
Case Report: Clinical Responses to Tislelizumab as a First-Line Therapy for Primary Hepatocellular Carcinoma With B-Cell Indolent Lymphoma
2021